June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Natural History of Individuals with Retinal Degeneration Due to Biallelic Mutations in the RPE65 Gene
Author Affiliations & Notes
  • Kathleen Z Reape
    Spark Therapeutics, Philadelphia, Pennsylvania, United States
  • Daniel C Chung
    Spark Therapeutics, Philadelphia, Pennsylvania, United States
  • Grace Schaefer
    Spark Therapeutics, Philadelphia, Pennsylvania, United States
  • Jennifer A. Wellman
    Spark Therapeutics, Philadelphia, Pennsylvania, United States
  • Emily Liu
    Spark Therapeutics, Philadelphia, Pennsylvania, United States
  • Julie Pappas
    Westat, Rockville, Maryland, United States
  • Okan Elci
    Westat, Rockville, Maryland, United States
  • Sarah McCague
    CHOP, Philadelphia, Pennsylvania, United States
  • Katherine A High
    Spark Therapeutics, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Kathleen Reape, Spark Therapeutics (E), Spark Therapeutics (I); Daniel Chung, Spark Therapeutics (E), Spark Therapeutics (I); Grace Schaefer, Spark Therapeutics (E), Spark Therapeutics (I); Jennifer Wellman, Spark Therapeutics (E), Spark Therapeutics (I); Emily Liu, Spark Therapeutics (E), Spark Therapeutics (I); Julie Pappas, Spark Therapeutics (F), Spark Therapeutics (C); Okan Elci, Spark Therapeutics (F), Spark Therapeutics (C); Sarah McCague, Spark Therapeutics (F), Spark Therapeutics (C); Katherine High, Spark Therapeutics (I), Spark Therapeutics (E)
  • Footnotes
    Support  Study sponsored by Spark Therapeutics
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1488. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Kathleen Z Reape, Daniel C Chung, Grace Schaefer, Jennifer A. Wellman, Emily Liu, Julie Pappas, Okan Elci, Sarah McCague, Katherine A High; Natural History of Individuals with Retinal Degeneration Due to Biallelic Mutations in the RPE65 Gene. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1488.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : With recent advances in gene-based and other therapies, the need exists for greater understanding of the progression of RPE65-mediated inherited retinal disease (IRD). A retrospective chart review of 70 individuals with IRD associated with confirmed biallelic mutations in the RPE65 gene was conducted to elucidate the natural history of the disease.

Methods : Clinical data, including visual acuity (VA), visual field (VF), optical coherence tomography (OCT), and other vision parameters, as well as background information (demographics, ocular history and examination, genetic and clinical diagnoses) were collected and analyzed from charts at seven tertiary referral centers worldwide. VA and VF data were presented previously; ocular findings are presented here.

Results : Statistically significant effects of age on VA (p<0.001) and Goldmann VF (p<0.0001) were observed. On OCT, no statistically significant age effect on foveal or outer nuclear layer thickness was observed although data were limited. On ocular history, 74% reported orientation and/or mobility issues and 80% reported use of low vision aids. More than half reported poor night vision, and more than 90% had a clinical diagnosis or onset of symptoms by the age of 18. Sixty subjects (86%) had some abnormality in color vision and 65 (93%) had refractive errors, with the majority being myopic. Nystagmus was present in almost 80%, and was not always accompanied by a clinical diagnosis of Leber congenital amaurosis. Approximately 20% had cataracts or lens abnormalities. Other structural abnormalities, while variable, generally appeared to increase with age, consistent with progressive retinal degeneration.

Conclusions : Despite limitations inherent in the retrospective design, this study provides important natural history information regarding the clinical course of the disease. Clinical findings, along with the heterogeneity in clinical diagnoses and genetic mutations support the need for genetic testing. Clear age-related declines in VA and VF, as well as structural abnormalities were observed, with no evidence of spontaneous, sustained improvement. Variability is high and the optimal therapeutic window is unknown, however therapeutic intervention (prior to extensive retinal degeneration) for RPE65-mediated IRD has the potential to alter the progressive natural history of this disease.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×